Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Esperion Therapeutics reports robust Q4 earnings, eyes global expansion

Esperion Therapeutics delivered strong financial results in Q4 2022, driven by successful formulary additions and international partner growth.
The company faces challenges in increasing brand awareness and effectively positioning bempedoic acid post statins, requiring strategic marketing and market access initiatives.
Opportunities lie in leveraging upcoming trial results for label expansion, enhancing brand visibility, and capitalizing on international growth through partnerships.

Esperion Therapeutics excels in Q1 2023, poised for market opportunities

Esperion Therapeutics delivered robust Q1 results with revenue growth and positive market reactions to its studies. While facing legal challenges and operational discussions, the company is well-positioned to leverage opportunities in the market through its strong partnerships and financial stability.

Esperion Therapeutics excels in Q2 earnings, eyes label expansion opportunities

Esperion Therapeutics delivered strong financial performance in Q2 2023, driven by revenue growth, cost management, and strategic partnerships.
While facing challenges in managing expenses, the company is well-positioned to capitalize on market opportunities post-label expansion approvals.
With a solid cash position, ongoing operational efficiency efforts, and a focus on growth initiatives, Esperion is poised for continued success.
The company's commitment to innovation and patient outcomes bodes well for its future growth trajectory and market competitiveness.

Esperion Therapeutics excels in Q3 earnings amidst regulatory hurdles

Esperion Therapeutics delivered strong financial results in Q3 2023, driven by revenue growth and strategic collaborations, despite facing regulatory and litigation challenges.
The company's focus on expanding market presence through FDA approvals and international expansion presents promising growth avenues for future success.
With a solid financial position and ongoing initiatives to drive prescription growth, Esperion is poised to capitalize on market opportunities and navigate challenges effectively.

Esperion Therapeutics reports robust Q4 earnings and eyes market expansion

Esperion Therapeutics delivered strong financial performance in Q4 2023, showcasing significant revenue growth and strategic advancements.
While facing challenges in managing expenses and executing growth strategies, the company is well-positioned to capitalize on market opportunities and drive future expansion.
With a clear roadmap for expense management and a focus on product reach and market expansion, Esperion is poised for continued growth and value creation for stakeholders.
The settlement agreement and label expansion approvals provide a solid foundation for Esperion to leverage opportunities, overcome challenges, and drive sustainable growth.

Esperion Therapeutics posts robust Q1 results amid FDA label wins

Esperion Therapeutics delivered strong financial performance in Q1 2024, driven by revenue growth and FDA label expansions.
The company faces challenges in maintaining prescription growth and navigating payer dynamics post-label update.
Strategic initiatives and market opportunities present avenues for Esperion to capitalize on its recent successes and drive future growth.

Esperion Therapeutics reports robust Q2 revenue growth and global expansion

Esperion Therapeutics delivered strong financial performance in Q2 2024, driven by revenue growth and successful market expansion efforts.
While facing challenges such as debt extinguishment losses and high operating expenses, the company capitalized on opportunities for international growth and product marketability.
By leveraging strengths in expanded product labels and improved market access, Esperion is poised to navigate challenges and capitalize on growth opportunities in the pharmaceutical sector.

Esperion Therapeutics reports robust Q3 performance and eyes global expansion

Esperion Therapeutics delivered strong financial performance in Q3 2024, driven by revenue growth and strategic initiatives to expand market access and product offerings.
While challenges in achieving profitability persist, the company's focus on innovation, global expansion, and operational efficiency underscores its long-term growth potential.
By leveraging strengths in collaboration, research, and market differentiation, Esperion is poised to capitalize on opportunities for further international expansion and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

ANN ARBOR, Mich., July  01, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine, was published in the Journal of the American Medical Association (JAMA) Cardiology.  The four Phase 3 clinical studies evaluated the efficacy and safety of NEXLETOL versus placebo in 3623 patients with hypercholesterolemia while receiving stable lipid-lowering therapy and at high cardiovascular risk or with hypercholesterolemia and statin intolerance.  NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined.

Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets

Esperion Therapeutics: An Easy Double, Maybe A Lot More

ANN ARBOR, Mich., June  22, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE).  Earlier this month, Esperion completed the transfer to DSE of Marketing Authorization Approvals (MAA) for NILEMDO and NUSTENDI.  DSE will now pay Esperion the second $150 million milestone based on completion of the MAA transfer rather than the first commercial product sale in the EU, as previously agreed.

Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement

ANN ARBOR, Mich., June  14, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American Diabetes Association 80th Scientific Sessions.  According to the American Diabetes Association (ADA) guidelines, elevated LDL cholesterol is a common problem for people with diabetes. Also referred to as hyperlipidemia, this condition greatly increases the risk of developing cardiovascular disease.

Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions

ANN ARBOR, Mich., June  12, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today confirms it has received notice that the Institute of Clinical and Economic Review (ICER) plans to assess new non-statin medicines for hypercholesterolemia in the U.S., including the clinical cost effectiveness and value of NEXLETOL.  A report completion is targeted for February 2021.  ICER generally only assesses medicines that are expected to have a meaningful impact in a therapeutic area.  Esperion anticipates the assessment will find the same conclusions as the extensive pricing and value work already completed and the broad and high-quality managed care coverage already achieved for NEXLETOL.

Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER

ANN ARBOR, Mich., June  08, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020, at 4:40 p.m. Eastern Time.

Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Why Is Esperion Therapeutics (ESPR) Down 1.5% Since Last Earnings Report?

Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy

– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – –  Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers –  – Launch Date Accelerated by One Month at Health Care Providers Request –

Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

Esperion: Early Commercial Success Supports A Buy At These Prices

Esperion Has A Low Bar To Climb To Warrant Its Present Valuation

Esperion Therapeutics' Festive Q1 2020 Earnings Call

Esperion Therapeutics (ESPR) reports encouraging first-quarter results. The company records product revenues for the first time during the quarter.

Esperion (ESPR) Q1 Earnings and Revenues Beat Estimates

Esperion Therapeutics' (ESPR) CEO Tim Mayleben on Q1 2020 Results - Earnings Call Transcript

–  Esperion to Receive $60 Million Upfront Payment  –

Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan

Aimmune Therapeutics

Epizyme

Horizon Pharma

These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.

Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?

Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.

Esperion's Cholesterol Drugs Receive Approval in Europe

– First Non-Statin, LDL-C Lowering Combination Medicine Ever Approved in Europe –

Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients –

Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option –  – Esperion Aims to Set New Industry Standard by Pricing NEXLETOL for Patient Affordability and Access –   – Company Repurposes Healthcare Provider Education and Support Material Encouraging Remote Education and Virtual Visits with our Lipid Experts During This Extraordinary Time –

Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound?

ANN ARBOR, Mich., March  28, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET were presented at the American College of Cardiology’s 69th Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology 

ANN ARBOR, Mich., March  18, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders.

Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors

ANN ARBOR, Mich., Feb.  28, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 26, 2020, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 10,900 shares of its common stock and 59,291 restricted stock units (RSUs) to 149 new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.

Esperion Announces  Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.

News for Esperion Therapeutics Stock (ESPR)